EVER Pharma gains EU Marketing Authorization for Trabectedin
EVER Pharma is pleased to announce the EU-wide marketing authorization of Trabectedin (in 0.25MG and 1MG vial sizes) for the treatment of advanced soft tissue sarcoma and ovarian cancer1.
Soft tissue sarcoma (STS) and ovarian cancer are rare forms of cancer affecting in total around 150,000 patients in the European Union. Trabectedin is recommended for treating advanced STS2. It is also an important treatment option for patients with relapsed ovarian cancer.
“Rare and late stage forms of cancer are often poorly served when it comes to available therapeutics. EVER Pharma is pleased to make this complex and technically challenging product available to patients living with these cancers. This is part of our commitment to improving patient access to essential pharmaceuticals” said Georges Kahwati, General Manager of EVER Pharma.
The European authorization of EVER Pharma’s Trabectedin is another important addition to the rapidly expanding EVER portfolio of specialty injectable products. The product is planned for roll out into major markets globally.
1Trabectedin EVER is indicated for (i) the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients, (ii) in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
2European Society for Medical Oncology—European Reference Network for rare adult solid cancers (ESMO-EURACAN) Clinical Practice Guidelines